Optimising diabetes management and improving utilisation of healthcare resources with insulin glargine biosimilars

Diabetes burden and associated complications are on the rise in Singapore and contribute to the increasing healthcare expenditure. Insulin biosimilars, with comparable efficacy and safety to the originator biologics, can help reduce both financial and disease burden. INSTRIDE-1/2 studies have proven biosimilar insulin glargine to be non-inferior to reference insulin glargine with no clinically meaningful differences in terms of efficacy and safety in type 1 and type 2 diabetes patients. Whilst INSTRIDE-3 has proven the switch from reference glargine to a cost-effective biosimilar insulin glargine to be a safe and feasible approach. There is a continued need to educate clinicians to help motivate patients and improve their awareness on biosimilars.